Moreover, cyclopeptide DC646 has high potential therapeutic benefit for the treatment of MASH in an intestinal FXR-dependent manner, along with a commendable safety profile. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.